Life Technologies Partners with German Cancer Research Center to Create World-Class Genome Sequencing Facility
News Jun 03, 2010
This exclusive partnership will create the largest sequencing facility in Germany and the first national sequencing center in Europe dedicated to systems biology.
The center will operate 10 SOLiD™ 4 hq systems acquired by DKFZ and will initially sequence 1000 whole human cancer genomes for Germany’s national contribution to the International Cancer Genome Consortium (ICGC). The facility will be partially funded by the German Federal Ministry of Education and Research.
Systems biology is the study of an organism as an integrated and interacting network of genes, proteins and biochemical reactions that give rise to life. Often, experiments in systems biology require precise measurements of cellular events over time and assess changes in DNA sequence, RNA transcription or genomic copy number. Therefore, these experiments require substantially more sequencing throughput than experiments that are not examining such dynamic changes in cellular events.
“Our aim is to understand the dynamic complexity of cellular processes on both the DNA and RNA level and how slight perturbations of those pathways contribute to the development of diseases like cancer,” said Professor Roland Eils from DFKZ. “Therefore, it is of the utmost importance to be able to obtain quantitative precise measurements. We are confident that this collaboration with Life Technologies will help us generate the highest quality data possible using the SOLiD™ technology.”
The SOLiD™ System is used globally in experiments to better understand the genetic nature of diseases such as cancer, diabetes, neurological disorders and other diseases. Its throughput, accuracy and flexibility allow researchers to generate the data they need for their experiments.
“Life Technologies is proud to be the technology partner of choice for this new and exciting sequencing center and to be working with DKFZ, a renowned institution in Germany in life science research devoted to studying the complexities of human diseases like cancer,” said Mark Stevenson, President and Chief Operating Officer for Life Technologies. “This center will be the first facility that will systematically bring high-throughput sequencing technologically into systems biology applications on a large scale.”
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE